Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Company Details
- Employees
- 74
- Founded
- -
- Address
- Three Bala Plaza East, Suite 506,united States
- Phone
- 844-511-9056
- in****@****rtx.com
- Industry
- Biotechnology
- Website
- https://larimartx.com
- Keywords
- Biotechnology and Rare Disease.
- HQ
- Bala Cynwyd, PA
Larimar Therapeutics Inc. Questions
Larimar Therapeutics Inc.'s helpline number is 844-511-9056
Larimar Therapeutics Inc.'s website is https://larimartx.com
Larimar Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/larimar-therapeutics
Larimar Therapeutics Inc. has
74 employees.
View email and phone details for 74
employees at Larimar Therapeutics Inc..
Larimar Therapeutics Inc.'s industry is
Biotechnology
Larimar Therapeutics Inc.'s top competitors are
Carisma Therapeutics,
Ptc Therapeutics, Inc.,
Lexeo Therapeutics,
Cabaletta Bio,
Swanbio Therapeutics,
Code Biotherapeutics,
Genisphere,
Spark Therapeutics, Inc.,
Adaptimmune,
Verismo Therapeutics.
Larimar Therapeutics Inc.'s support email address is info@larimartx.com
Larimar Therapeutics Inc.'s categories are Biotechnology
Larimar Therapeutics Inc.'s founding year is 2016
